Taxane benefit in breast cancer—a role for grade and chromosomal stability

被引：0

作者：

Roger P. A'Hern

Mariam Jamal-Hanjani

A. Marcell Szász

Stephen R. D. Johnston

Jorge S. Reis-Filho

Rebecca Roylance

Charles Swanton

机构：

[1] Cancer Research UK Section of Clinical Trials,2nd Department of Pathology

[2] The Institute of Cancer Research,Department of Pathology

[3] Translational Cancer Therapeutics Laboratory,undefined

[4] Cancer Research UK,undefined

[5] London Research Institute,undefined

[6] Semmelweis University,undefined

[7] Memorial Sloan–Kettering Cancer Center,undefined

[8] Barts Cancer Institute,undefined

[9] Queen Mary University of London,undefined

来源：

Nature Reviews Clinical Oncology | 2013年 / 10卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

In this Perspectives article, the authors propose that lower histological grade in breast cancer might be a hallmark of relative chromosomal stability, which in turn might be predictive of additional benefit from taxane-based chemotherapy in women with oestrogen-receptor-positive cancer. They interpret published data to on the relationships between tumour grade, chromosomal instability and intratumour heterogeneity and discuss the potential use of chromosomal instability to tailor therapy.

引用

页码：357 / 364

页数：7

共 50 条

[21] Histologic Grade 1 in Breast Cancer Indicates a Lack of Benefit in Ordering Oncotype DX
Sanders, Mary Ann
Riley, Elizabeth C.
LABORATORY INVESTIGATION, 2016, 96 : 70A - 70A
[22] The role of the genomic breast cancer index in predicting pathologic complete response in breast cancer patients treated with neoadjuvant anthracycline plus taxane
Mathieu, M. C.
Kesty, N. C.
Li, H.
Scott, V.
Marty, V.
Viehl, P.
Delacruz, J.
Delaloge, S.
Schnabel, C.
Erlander, M. G.
Andre, F.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[23] Correlation of morphological markers of chromosomal instability in fine needle aspiration cytology with grade of breast cancer
Verma, S.
Dey, P.
CYTOPATHOLOGY, 2014, 25 (04) : 259 - 263
[24] Platinum–Taxane Combinations in Metastatic Breast Cancer: An Evolving Role in the Era of Molecularly Targeted Therapy
John Crown
Mark Pegram
Breast Cancer Research and Treatment, 2003, 79 (Suppl 1) : 11 - 18
[25] Taxane-containing regimens for metastatic breast cancer
Ghersi, Davina
Willson, Melina L.
Chan, Matthew Ming Ki
Simes, John
Donoghue, Emma
Wilcken, Nicholas
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (06):
[26] STATHMIN, A PREDICTIVE BIOMARKER FOR TAXANE RESPONSE IN BREAST CANCER?
Knappskog, S.
Mauland, K. K.
Hoivik, E.
Salvesen, H. B.
Trovik, J.
Lonning, P. E.
Werner, H. M.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 49 - 49
[27] Selection of a taxane as well as anthracycline for early breast cancer
Graham, Peter H.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) : 2416 - 2417
[28] Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane
Moreno-Aspitia, Alvaro
Perez, Edith A.
MAYO CLINIC PROCEEDINGS, 2009, 84 (06) : 533 - 545
[29] Taxane induced pulmonary toxicity in breast cancer.
Varayathu, Hrishi
Mathew, Hephzibah Sara
Sarathy, Vinu
Thomas, Beulah Elsa
Kumar, Santosh Elluru
Reddy, Nitheesha
Mufti, Suhail Sayeed
Puii, Lalnun
Sangi, Lalram
Mathew, Smruthy Ann
Koramati, Samuel Luke
Dinesh, S.
Swamy, Shivakumar
Naik, Radheshyam
Ajaikumar, Basavalinga Sadasivaiah
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[30] Safety of Taxane Chemotherapy in Breast Cancer During Pregnancy
O'Laughlin, Andie
So, Samantha
Fleischer, Lindsay
Akoto, Serwaa
Cardonick, Elyce
OBSTETRICS AND GYNECOLOGY, 2019, 133 : 169S - 170S

← 1 2 3 4 5 →